Mumbai, Jan. 27
LUPIN has tied up with Cornerstone BioPharma Inc to promote Suprax in the US. Suprax is Lupin's brand of the anti-infective drug cefixime.
Lupin's sales-force in the US has been promoting this drug to paediatricians and the new deal seeks to expand this coverage to primary care physicians as well.
The deal was inked with Lupin Pharmaceuticals Inc (LPI), a wholly owned subsidiary of Lupin. Cornerstone's sales-force will co-promote Suprax, a Lupin release issued here on Thursday said.
Cornerstone BioPharma is a non-traditional speciality pharmaceutical company focused in the pain, wound healing and respiratory markets. It's primary focus for Suprax will be to promote the product to primary care physicians, who were not covered by Lupin's sales-force, the note said. The deal is also significant since Lupin has been incurring promotional costs on account of this product, a pharma analyst said.
Suprax was approved in 2004 and was promoted by LPI's paediatric-focused sales-force, the note said. The partnership represents a significant expansion in the scope of physician coverage for Suprax in the $1.2-billion US oral suspension anti-infective market.